Zymergen Inc.
DelistedCIK 1645842fmd_0M2JQ75D6BVJAV4SGZ0957SQPGServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2022, 11 periods
| Line item | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Total revenues | 15 | 13 | 17 |
| Cost of revenue | 103 | 85 | 70 |
| Gross profit | (87) | (72) | (53) |
| Research and development | 51 | 91 | 159 |
| Selling, general and administrative | 85 | 79 | 107 |
| Operating income | (237) | (241) | (348) |
| Interest expense | 3 | 11 | 15 |
| Interest and investment income | 5 | 0 | 0 |
| Other non-operating income (expense) | 0 | (21) | (14) |
| Income before taxes | (237) | (262) | (362) |
| Income tax expense | 0 | (0) | 0 |
| Net income from continuing operations | (237) | (262) | (362) |
| Net income | (237) | (262) | (362) |
| Net income to common shareholders | (237) | (262) | (362) |